Identification of Covert Atrial Fibrillation in Cryptogenic Ischemic Stroke

Current Clinical Practice in Japan

Kazunori Toyoda, Ken Okumura, Yoichiro Hashimoto, Takanori Ikeda, Takashi Komatsu, Teruyuki Hirano, Haruhisa Fukuda, Kazuo Matsumoto, Masahiro Yasaka

研究成果: ジャーナルへの寄稿評論記事

8 引用 (Scopus)

抄録

Background and aim A new insertable cardiac monitor, Reveal LINQ (Medtronic, Dublin, Ireland), was approved for clinical use in Japan in March 2016 for detecting atrial fibrillation in patients who develop ischemic stroke with no clearly definable etiology even after extensive workup, so-called cryptogenic ischemic stroke. Cooperation between a specialist of the Japan Stroke Society and a trained cardiologist or cardiac surgeon is needed both for appropriate patient selection and appropriate management of the device. In this paper, the clinical significance of and diagnostic methods for cryptogenic stroke and covert atrial fibrillation are explained, along with our proposal for the clinical indications for this new device. Methods, results, and conclusion The majority of cryptogenic ischemic strokes are considered to be embolic. In particular, covert atrial fibrillation is drawing attention as the causal emboligenic disease, and it was identified in 30% of patients with long-term observation using an insertable cardiac monitor. Should atrial fibrillation be present, there is a high risk of recurrent stroke, and the cardioembolic stroke that appears is generally severe. The ability to identify atrial fibrillation would be beneficial for preventing stroke recurrence, as anticoagulants can then be used as an established method of secondary prevention. Because the use of insertable cardiac monitors is somewhat invasive, and long-term care systems are also needed, patients suitable for examination using the new device would need to be identified on the basis of detailed diagnostics in accordance withcurrent medical practice in Japan.

元の言語英語
ページ(範囲)1829-1837
ページ数9
ジャーナルJournal of Stroke and Cerebrovascular Diseases
25
発行部数8
DOI
出版物ステータス出版済み - 8 1 2016

Fingerprint

Atrial Fibrillation
Japan
Stroke
Equipment and Supplies
Long-Term Care
Secondary Prevention
Ireland
Anticoagulants
Patient Selection
Observation
Recurrence

All Science Journal Classification (ASJC) codes

  • Surgery
  • Rehabilitation
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

これを引用

Identification of Covert Atrial Fibrillation in Cryptogenic Ischemic Stroke : Current Clinical Practice in Japan. / Toyoda, Kazunori; Okumura, Ken; Hashimoto, Yoichiro; Ikeda, Takanori; Komatsu, Takashi; Hirano, Teruyuki; Fukuda, Haruhisa; Matsumoto, Kazuo; Yasaka, Masahiro.

:: Journal of Stroke and Cerebrovascular Diseases, 巻 25, 番号 8, 01.08.2016, p. 1829-1837.

研究成果: ジャーナルへの寄稿評論記事

Toyoda, Kazunori ; Okumura, Ken ; Hashimoto, Yoichiro ; Ikeda, Takanori ; Komatsu, Takashi ; Hirano, Teruyuki ; Fukuda, Haruhisa ; Matsumoto, Kazuo ; Yasaka, Masahiro. / Identification of Covert Atrial Fibrillation in Cryptogenic Ischemic Stroke : Current Clinical Practice in Japan. :: Journal of Stroke and Cerebrovascular Diseases. 2016 ; 巻 25, 番号 8. pp. 1829-1837.
@article{415e76a269e345949f8aa31d396d5a32,
title = "Identification of Covert Atrial Fibrillation in Cryptogenic Ischemic Stroke: Current Clinical Practice in Japan",
abstract = "Background and aim A new insertable cardiac monitor, Reveal LINQ (Medtronic, Dublin, Ireland), was approved for clinical use in Japan in March 2016 for detecting atrial fibrillation in patients who develop ischemic stroke with no clearly definable etiology even after extensive workup, so-called cryptogenic ischemic stroke. Cooperation between a specialist of the Japan Stroke Society and a trained cardiologist or cardiac surgeon is needed both for appropriate patient selection and appropriate management of the device. In this paper, the clinical significance of and diagnostic methods for cryptogenic stroke and covert atrial fibrillation are explained, along with our proposal for the clinical indications for this new device. Methods, results, and conclusion The majority of cryptogenic ischemic strokes are considered to be embolic. In particular, covert atrial fibrillation is drawing attention as the causal emboligenic disease, and it was identified in 30{\%} of patients with long-term observation using an insertable cardiac monitor. Should atrial fibrillation be present, there is a high risk of recurrent stroke, and the cardioembolic stroke that appears is generally severe. The ability to identify atrial fibrillation would be beneficial for preventing stroke recurrence, as anticoagulants can then be used as an established method of secondary prevention. Because the use of insertable cardiac monitors is somewhat invasive, and long-term care systems are also needed, patients suitable for examination using the new device would need to be identified on the basis of detailed diagnostics in accordance withcurrent medical practice in Japan.",
author = "Kazunori Toyoda and Ken Okumura and Yoichiro Hashimoto and Takanori Ikeda and Takashi Komatsu and Teruyuki Hirano and Haruhisa Fukuda and Kazuo Matsumoto and Masahiro Yasaka",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.jstrokecerebrovasdis.2016.05.012",
language = "English",
volume = "25",
pages = "1829--1837",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - Identification of Covert Atrial Fibrillation in Cryptogenic Ischemic Stroke

T2 - Current Clinical Practice in Japan

AU - Toyoda, Kazunori

AU - Okumura, Ken

AU - Hashimoto, Yoichiro

AU - Ikeda, Takanori

AU - Komatsu, Takashi

AU - Hirano, Teruyuki

AU - Fukuda, Haruhisa

AU - Matsumoto, Kazuo

AU - Yasaka, Masahiro

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background and aim A new insertable cardiac monitor, Reveal LINQ (Medtronic, Dublin, Ireland), was approved for clinical use in Japan in March 2016 for detecting atrial fibrillation in patients who develop ischemic stroke with no clearly definable etiology even after extensive workup, so-called cryptogenic ischemic stroke. Cooperation between a specialist of the Japan Stroke Society and a trained cardiologist or cardiac surgeon is needed both for appropriate patient selection and appropriate management of the device. In this paper, the clinical significance of and diagnostic methods for cryptogenic stroke and covert atrial fibrillation are explained, along with our proposal for the clinical indications for this new device. Methods, results, and conclusion The majority of cryptogenic ischemic strokes are considered to be embolic. In particular, covert atrial fibrillation is drawing attention as the causal emboligenic disease, and it was identified in 30% of patients with long-term observation using an insertable cardiac monitor. Should atrial fibrillation be present, there is a high risk of recurrent stroke, and the cardioembolic stroke that appears is generally severe. The ability to identify atrial fibrillation would be beneficial for preventing stroke recurrence, as anticoagulants can then be used as an established method of secondary prevention. Because the use of insertable cardiac monitors is somewhat invasive, and long-term care systems are also needed, patients suitable for examination using the new device would need to be identified on the basis of detailed diagnostics in accordance withcurrent medical practice in Japan.

AB - Background and aim A new insertable cardiac monitor, Reveal LINQ (Medtronic, Dublin, Ireland), was approved for clinical use in Japan in March 2016 for detecting atrial fibrillation in patients who develop ischemic stroke with no clearly definable etiology even after extensive workup, so-called cryptogenic ischemic stroke. Cooperation between a specialist of the Japan Stroke Society and a trained cardiologist or cardiac surgeon is needed both for appropriate patient selection and appropriate management of the device. In this paper, the clinical significance of and diagnostic methods for cryptogenic stroke and covert atrial fibrillation are explained, along with our proposal for the clinical indications for this new device. Methods, results, and conclusion The majority of cryptogenic ischemic strokes are considered to be embolic. In particular, covert atrial fibrillation is drawing attention as the causal emboligenic disease, and it was identified in 30% of patients with long-term observation using an insertable cardiac monitor. Should atrial fibrillation be present, there is a high risk of recurrent stroke, and the cardioembolic stroke that appears is generally severe. The ability to identify atrial fibrillation would be beneficial for preventing stroke recurrence, as anticoagulants can then be used as an established method of secondary prevention. Because the use of insertable cardiac monitors is somewhat invasive, and long-term care systems are also needed, patients suitable for examination using the new device would need to be identified on the basis of detailed diagnostics in accordance withcurrent medical practice in Japan.

UR - http://www.scopus.com/inward/record.url?scp=84971634547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971634547&partnerID=8YFLogxK

U2 - 10.1016/j.jstrokecerebrovasdis.2016.05.012

DO - 10.1016/j.jstrokecerebrovasdis.2016.05.012

M3 - Review article

VL - 25

SP - 1829

EP - 1837

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 8

ER -